title: Magnitude of activity in chronic hepatitis C is influenced by apoptosis of T cells responsible for hepatitis C virus.
abstract: BACKGROUND
  The mechanisms of hepatitis C virus (HCV) persistence are unknown, but down-regulation of immune response in a host is likely to play a major role in it.
  
  
  METHODS
  To investigate whether T cell apoptosis contributes to such down-regulation, we compared peripheral T cell apoptosis in patients with chronic hepatitis C (CHC) with the serum titre of HCV-RNA, serum alanine aminotransferase (sALT) levels and its change, or peripheral T cell proliferation to the recombinant core antigen of HCV, JCC-1.
  
  
  RESULTS
  The percentage of apoptosis in T cells was 0.30 +/- 0.31% (mean +/- SD) in 44 patients with CHC and 0.10 +/- 0.05% in 10 normal volunteers (P < 0.05). In patients with CHC there was no statistical correlation between apoptosis in T cells and sALT levels, titre of HCV-RNA or T cell proliferation to JCC-1 antigen. But, in patients showing relatively more apoptosis in T cells (more than mean + 2SD of apoptosis in T cells from normal volunteers), sALT levels decreased.
  
  
  CONCLUSIONS
  Thus, T cell apoptosis in patients with CHC is considered to cause a reduction in sALT, contributing to HCV persistence in patients with CHC.
authors.affiliation: First Department of Internal Medicine, School of Medicine, Fukuoka University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Emi
authors.forename: K
authors.initials: K
authors.lastname: Nakamura
authors.forename: K
authors.initials: K
authors.lastname: Yuh
authors.forename: S
authors.initials: S
authors.lastname: Sugyo
authors.forename: H
authors.initials: H
authors.lastname: Shijo
authors.forename: M
authors.initials: M
authors.lastname: Kuroki
authors.forename: K
authors.initials: K
authors.lastname: Tamura
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D017209:Apoptosis / Q000276:immunology*; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005260:Female; D016174:Hepacivirus / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000276:immunology* / Q000378:metabolism / Q000821:virology*; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D014758:Viral Core Proteins / Q000276:immunology / Q000494:pharmacology; D017735:Virus Latency / Q000276:immunology; D019014:fas Receptor / Q000096:biosynthesis
chemical_list: D012367:RNA, Viral; D014758:Viral Core Proteins; D019014:fas Receptor; C069130:nucleocapsid protein, Hepatitis C virus; D000410:Alanine Transaminase